Immunome's Stock Jumps On Its Antibody Cocktail Neutralizing Multiple COVID-19 Variants In Animal Studies

  • Immunome Inc IMNM has announced antibody selection for its IMM-BCP-01 antibody cocktail and shared preclinical data showing that IMM-BCP-01 is effective against the current SARS-CoV-2 and its variants.
  • In Syrian hamsters infected with live SARS-CoV-2 virus, IMM-BCP-01 reduced lung viral load as a treatment and prophylaxis. 
  • Data also demonstrated full neutralization by IMM-BCP-01 of emerging/concerning variants of COVID-19 and mutations.
  • Mechanistic studies demonstrate that the selected antibodies bind not only to SARS-CoV-2 spike proteins with complex mutations but also to those with several individual mutations.
  • Two of the three selected antibodies bind to areas of the Spike protein that may be resistant to evolutionary change.
  • Immunome anticipates filing an IND for its IMM-BCP-001 program in late Q2/early Q3 2021.
  • IMM-BCP-01 contains three monoclonal antibodies that bind to non-overlapping regions of the spike protein with picomolar affinity.
  • Price Action: IMNM shares are trading 12.7% higher at $33.29 in the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!